| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 79, 1778-1784, Copyright © 1994 by Endocrine Society
ARTICLES |
L Ibanez, N Potau, M Zampolli, N Prat, M Gussinye, P Saenger, E Vicens-Calvet and A Carrascosa
Endocrinology Unit, Hospital Materno-Infantil Vall d'Hebron, Autonomous University, Barcelona, Spain.
Functional ovarian hyperandrogenism (FOH) is characterized by an abnormal ovarian response to challenge with the GnRH analogs nafarelin and leuprolide acetate, similar to that observed in women with well defined polycystic ovary syndrome, regardless of whether elevated LH levels or polycystic ovaries are present. We studied an unselected group of 42 hyperandrogenic adolescents (age range, 14-22 yr; mean, 18.1 +/- 2.5 yr) 1) to determine FOH incidence through the assessment of ovarian-steroidogenic response to a single dose of leuprolide acetate, 2) to assess the clinical characteristics of patients according to their responses to GnRH analog stimulation, and 3) to evaluate adrenal steroidogenic function and its relation to ovarian hyperandrogenism in patients with either normal or abnormal responses to leuprolide acetate challenge. All patients underwent leuprolide acetate and ACTH testing, dexamethasone and ovarian suppression tests, and pelvic ultrasonography. Twenty-four (58%) patients had supranormal plasma 17-hydroxyprogesterone (17-OHP) responses to leuprolide acetate characteristic of FOH, and in 18, the 17-OHP response was similar to that of controls (n = 24; age, 17.1 +/- 2.3 yr). Seven patients (5 with FOH and 2 with normal responses to leuprolide acetate) had an abnormal response to ACTH, but only 1 had conclusive evidence of 21-hydroxylase deficiency. In 16 patients, the response to both stimulation tests was normal. Only 13 (54%) of the 24 FOH patients had polycystic ovaries on ultrasonography, and in 11 (46%), basal plasma LH levels were elevated. In FOH patients, reduction in testosterone and androstenedione plasma levels was significantly greater after ovarian suppression than after dexamethasone challenge (P < 0.0005 and P < 0.02, respectively). Peak plasma 17-OHP levels postleoprolide acetate simulation correlated with dexamethasone-suppressed plasma testosterone concentrations, dexamethasone-suppressed plasma androstenedione levels, and the free androgen index postdexamethasone treatment (r = 0.4, P = 0.01; r+ 0.4, P < 0.05; and r = 0.41, P = 0.007, respectively), Plasma sex hormone- binding globulin levels after dexamethasone administration correlated negatively with the baseline free androgen index (r = -.0.67; P < 0.0001). Considering our diagnostic criteria, 26 (62%) of our collective of 42 patients had abnormal responses to one or both stimulation tests, whereas 16 (37%) had normal response. FOH is the most common cause in (58%) of androgen excess in adolescence. Short term leuprolide acetate stimulation is a reliable tool fro identification of the ovary as the source of their hyperandrogenism.
This article has been cited by other articles:
 |
|
 |
|
  D. S. Wachs, M. S. Coffler, P. J. Malcom, S. Shimasaki, and R. J. Chang Increased Androgen Response to Follicle-Stimulating Hormone Administration in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1827 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Saenger, P. Czernichow, I. Hughes, and E. O. Reiter Small for Gestational Age: Short Stature and Beyond Endocr. Rev., April 1, 2007; 28(2): 219 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Diamanti-Kandarakis and C. Piperi Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth Hum. Reprod. Update, November 1, 2005; 11(6): 631 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Petry, K. K. Ong, K. F. Michelmore, S. Artigas, D. L. Wingate, A. H. Balen, F. de Zegher, L. Ibanez, and D. B. Dunger Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women Hum. Reprod., July 1, 2005; 20(7): 1837 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez, C. Valls, S. Cabre, and F. de Zegher Flutamide-Metformin Plus Ethinylestradiol-Drospirenone for Lipolysis and Antiatherogenesis in Young Women with Ovarian Hyperandrogenism: The Key Role of Early, Low-Dose Flutamide J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4716 - 4720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez and F. de Zegher Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity Hum. Reprod., August 1, 2004; 19(8): 1725 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez and F. de Zegher Ethinylestradiol-Drospirenone, Flutamide-Metformin, or Both for Adolescents and Women with Hyperinsulinemic Hyperandrogenism: Opposite Effects on Adipocytokines and Body Adiposity J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1592 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez and F. de Zegher Flutamide-Metformin Therapy to Reduce Fat Mass in Hyperinsulinemic Ovarian Hyperandrogenism: Effects in Adolescents and in Women on Third-Generation Oral Contraception J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4720 - 4724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez, K. K. Ong, N. Mongan, J. Jaaskelainen, M. V. Marcos, I. A. Hughes, F. de Zegher, and D. B. Dunger Androgen Receptor Gene CAG Repeat Polymorphism in the Development of Ovarian Hyperandrogenism J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3333 - 3338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez, K. Ong, A. Ferrer, R. Amin, D. Dunger, and F. de Zegher Low-Dose Flutamide-Metformin Therapy Reverses Insulin Resistance and Reduces Fat Mass in Nonobese Adolescents with Ovarian Hyperandrogenism J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2600 - 2606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez and F. de Zegher Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome Hum. Reprod., January 1, 2003; 18(1): 57 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez, N. Potau, A. Ferrer, F. Rodriguez-Hierro, M. V. Marcos, and F. de Zegher Anovulation in Eumenorrheic, Nonobese Adolescent Girls Born Small for Gestational Age: Insulin Sensitization Induces Ovulation, Increases Lean Body Mass, and Reduces Abdominal Fat Excess, Dyslipidemia, and Subclinical Hyperandrogenism J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5702 - 5705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez, N. Potau, A. Ferrer, F. Rodriguez-Hierro, M. V. Marcos, and F. de Zegher Reduced Ovulation Rate in Adolescent Girls Born Small for Gestational Age J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3391 - 3393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez, C. Valls, A. Ferrer, K. Ong, D. B. Dunger, and F. de Zegher Additive Effects of Insulin-Sensitizing and Anti-Androgen Treatment in Young, Nonobese Women with Hyperinsulinism, Hyperandrogenism, Dyslipidemia, and Anovulation J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2870 - 2874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez, C. Valls, M. Cols, A. Ferrer, M. V. Marcos, and F. de Zegher Hypersecretion of FSH in Infant Boys and Girls Born Small for Gestational Age J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 1986 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibáñez, J. DiMartino-Nardi, N. Potau, and P. Saenger Premature Adrenarche--Normal Variant or Forerunner of Adult Disease? Endocr. Rev., December 1, 2000; 21(6): 671 - 696. [Abstract] [Full Text]
|
|
|
|
|
|
Corticotropin-Releasing Hormone: A Potent Androgen Secretagogue in Girls with Hyperandrogenism after Precocious Pubarche J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4602 - 4606. [Abstract] [Full Text]
|
|
|
|
|
|
L. Ibáñez, F. de Zegher, and N. Potau Anovulation after Precocious Pubarche: Early Markers and Time Course in Adolescence J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2691 - 2695. [Abstract] [Full Text]
|
|
|
|
|
|
L. Ibáñez, N. Potau, I. Francois, and F. de Zegher Precocious Pubarche, Hyperinsulinism, and Ovarian Hyperandrogenism in Girls: Relation to Reduced Fetal Growth J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3558 - 3562. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Gussinye, A. Carrascosa, N. Potau, M. Enrubia, E. Vicens-Calvet, L. Ibanez, and D. Yeste Bone Mineral Density in Prepubertal and in Adolescent and Young Adult Patients With the Salt-wasting Form of Congenital Adrenal Hyperplasia Pediatrics, October 1, 1997; 100(4): 671 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Jakubowicz and J. E. Nestler 17{alpha}-Hydroxyprogesterone Responses to Leuprolide and Serum Androgens in Obese Women with and without Polycystic Ovary Syndrome after Dietary Weight Loss J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 556 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Nestler and D. J. Jakubowicz Decreases in Ovarian Cytochrome P450c17{alpha} Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary Syndrome N. Engl. J. Med., August 29, 1996; 335(9): 617 - 623. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
